Formulary Monographs [DRONABINOL, 5622]
|
|
DRONABINOL
|
|
|
|
|
|
ANTIEMETICS
|
|
|
Synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss
|
|
|
The most frequent adverse effects of dronabinol include abdominal pain, nausea and vomiting, dizziness, euphoria, paranoid reactions, and somnolence. Seizures and seizure-like activity have been reported; dronabinol should be used with caution in those with a history of seizure disorders, and therapy should be stopped if seizures occur.
|
|
|
Nausea and vomiting associated with chemotherapy. Dose is based on body surface area and is determined by the physician. The usual initial oral dose of dronabinol is 5 mg/m2 given 1 to 3 hours before the first dose of the antineoplastic drug with subsequ
|
|
|
|
|
|
|
|
|
|
|
|
|